[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100183999":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"IgG4-RD",null,"Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.",[13,17],{"name":14,"affiliation":15,"role":16},"Wen Zhang, MD","Deptment of Rheumatology, Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":15,"role":19},"Fengchun Zhang","STUDY_CHAIR",[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Hua Chen, MD","CONTACT","86-10-69158797","chen77hua@gmail.com",[27],{"facility":15,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Beijing","Beijing Municipality","100032","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41,44],{"name":14,"role":23,"phone":42,"phoneExt":10,"email":43},"86-10-69158795","zhangwen91@sina.com",{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":16,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Wen Zhang","Professor","100183999","a-prospective-cohort-study-of-igg4rd-in-china-100183999",false,"NCT01670695","A Prospective Cohort Study of IgG4RD in China","Cohort Study of Patients With IgG4-Related Disease","Inclusion Criteria:\n\n* Males and females\n* Age 18-75 years old with informed consent\n* Patients with IgG4-RD:\n\n  1. swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions;\n  2. elevated serum IgG4 (\\>1.35 g\u002FL)\n  3. histopathologic features of fibrosis and\u002For lymphocytic and polyclonal plasma cell infiltration (and IgG4+ plasma cells on immunohistology when performed);\n  4. exclusion of other diseases.\n\nExclusion Criteria:\n\n* Females planning to bear a child recently or with childbearing potential\n* Concurrent severe and\u002For uncontrolled and\u002For unstable diseases\n* Patient with malignancy","ALL","18 Years","75 Years",{"count":59,"type":60},1000,"ESTIMATED","OBSERVATIONAL","This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.",[64],"IgG4-related Disease",[66,9],"IgG4-related disease","2017-04-07",{"date":69,"type":70},"2017-04-11","ACTUAL",{"date":72,"type":70},"2012-01",{"date":74,"type":60},"2032-01",{"name":5,"class":6},1]